4512 — Wakamoto Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapNeutral

Annual income statement for Wakamoto Pharmaceutical, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,383	8,660	7,738	7,789	9,907
Cost of Revenue
Gross Profit	4,356	4,108	3,600	3,622	4,730
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	8,402	8,550	7,989	8,251	9,652
Operating Profit	-18.8	110	-250	-461	255
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	285	212	159	7.46	256
Provision for Income Taxes
Net Income After Taxes	239	138	109	64.4	227
Net Income Before Extraordinary Items
Net Income	239	138	109	64.4	227
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	239	138	109	64.4	227
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7	4.57	4.22	1.92	6.57
Dividends per Share